Skip to Content
Biotechnology and health

Don’t hold your breath for allergy-free cats

Gene-editing technology is eyed as the next step in the quest to create cats that don’t make you sneeze.
Benjamin Svobodny | Pexels

Two US companies say they plan to use gene editing to modify cats so they don’t cause allergies.

Indoor Biotechnologies, based in Charlottesville, Virginia, and Felix Pets, outside of Denver, each say they have filed patents on the idea and that early experiments are under way.

Allergy sufferers probably shouldn’t count on sneeze-free cats soon, though. Both efforts remain small, and cat lovers have been disappointed before.

Back in 2009, a company called Allerca received wide media attention when it promised to use genetic tests to deliver allergy-free kittens. The cost of the cats reportedly ranged from $4,000 to more than $7,000 each.

Yet Allerca’s promises were apparently hollow. In 2013, an ABC report found that a kitten Allerca tried to sell reporters was an ordinary cat from a local pet breeder. (Allerca did not respond to attempts at contact.)

Gene modification remains an alluring solution to the allergy problem. Other treatments are imperfect: allergy shots can have spotty results, and clinical trials to develop a vaccine have failed. “Hypoallergenic” cat breeds will still make your eyes water.

By and large, people who have cat allergies are reacting to a single protein known as Fel d 1, which probably has a role in keeping cats’ skin healthy and may also interact with their hormonal systems. Male cats make the most Fel d 1; neutered toms make slightly less, and female cats less than that.

Martin Chapman, the CEO of Indoor Biotechnologies and a former professor of medicine and microbiology at the University of Virginia, says ever since scientists identified the protein, they’ve wondered “what would it be like if we could really get rid of [it].”

Gene editing now makes that easy to do, in theory. Chapman says his lab hopes to use the gene-editing tool CRISPR to try to remove the gene that makes Fel d 1 from cat cells.

However, it’s still not simple to actually generate an edited cat, a process that could involve cloning and working with embryos.

“Getting actual animals is likely the harder part, not editing the genes,” says Peggy Ozias-Akins, a horticulturist at the University of Georgia and director of the Institute of Plant Breeding, Genetics, and Genomics, who has worked on creating a less allergenic peanut.

There are also lingering questions about whether cats without Fel d 1 will be healthy. No one is sure what will happen to a cat’s body if the gene is removed. 

David Avner, founder of Felix Pets, says he has been trying to make an allergy-free cat since about 2004 on a shoestring budget. He says investors like the idea but want to see a cat before they invest. 

“Everyone understands it right away—they’re enamored with it,” says Avner. “They want to be a part of it—once the animal is produced and they’re assured that it’s allergen free, like we claim.”

Deep Dive

Biotechnology and health

Scientists are finding signals of long covid in blood. They could lead to new treatments.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

The first gene-editing treatment: 10 Breakthrough Technologies 2024

Sickle-cell disease is the first illness to be beaten by CRISPR, but the new treatment comes with an expected price tag of $2 to $3 million.

Weight-loss drugs: 10 Breakthrough Technologies 2024

Weight-loss drugs like Wegovy and Mounjaro are wildly popular and effective, but their long-term health impacts are still unknown.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.